The aim of this study was to evaluate the outcome after paclitaxel-eluting stent implantation in 40 patients with 52 saphenous vein graft lesions. By Kaplan-Meier estimates, the probability of major adverse cardiac event-free survival for 1 year was 92.5%. A paclitaxel-eluting stent for saphenous vein graft disease appears to be feasible and safe, with a low rate of reintervention at 1 year, but late follow-up is needed to confirm these observations.,
The American Journal of Cardiology
Erasmus MC: University Medical Center Rotterdam

Tsuchida, K., Ong, A., Aoki, J., van Mieghem, C., Rodriguez-Granillo, G., Valgimigli, M., … Serruys, P. (2005). Immediate and one-year outcome of percutaneous intervention of saphenous vein graft disease with Paclitaxel-eluting stents. The American Journal of Cardiology, 96(3), 395–398. doi:10.1016/j.amjcard.2005.03.084